Intraportal and Intraperitoneal Chemotherapy for Colon Cancer

作者: Werner Scheithauer

DOI: 10.1007/978-1-59259-160-2_33

关键词: OncologyVenous bloodAnticancer drugDrugColorectal cancerGastroenterologyArteryInternal medicineImmune defensePrimary tumorIntraperitoneal chemotherapyMedicine

摘要: Metachronous liver metastases are present at the time of initial diagnosis colorectal cancer in approx 25–30% patients (1). Similarly, is most common and sometimes only site distant failure after potential curative surgical resection (2). Colorectal reach via portal vein such dissemination may occur preoperatively intraoperatively. Operative stress immediate postoperative decrease immune defense, fact, have been shown some experimental models to improve survival malignant cells facilitate their growth (3). Fisher Turnbull discovered tumor mesenteric venous blood 32% (4), 1957, Dukes found evidence spread 17% operative rectal specimens (5). Despite continuing controversies, established seem be fed primarily by hepatic artery, whereas micrometastases likely depend on (6,7). Thus, early regional administration chemotherapeutic agents into (resulting high anticancer drug concentrations) might particularly beneficial, destroying suspected before can take place. Ideally, treatment should commenced shortly primary tumor, because more sensitive a given due shorter cell-cycle time, better accessibility drugs, smaller chance harboring resistance (8,9).

参考文章(46)
J.T. Evans, S.S. Schultz, S. Bakshi, A. Mittelman, K.L. Parthasarathy, B.J. Cedermark, The value of liver scan in the follow-up study of patients with adenocarcinoma of the colon and rectum. Surgery gynecology & obstetrics. ,vol. 144, pp. 745- ,(1977)
Paul H. Sugarbaker, Jerry M. Collins, Robert L. Dedrick, Charles E. Myers, James L. Speyer, Raymond W. Klecker, Portal Levels and Hepatic Clearance of 5-Fluorouracil after Intraperitoneal Administration in Humans Cancer Research. ,vol. 41, pp. 1916- 1922 ,(1981)
Daphne Tong, Anthony H. Russell, Lynne E. Dawson, William Wisbeck, Second laparotomy for proximal colon cancer The American Journal of Surgery. ,vol. 145, pp. 382- 386 ,(1983) , 10.1016/0002-9610(83)90207-6
N Wolmark, H Rockette, D L Wickerham, B Fisher, C Redmond, E R Fisher, M Potvin, R J Davies, J Jones, A Robidoux, Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. Journal of Clinical Oncology. ,vol. 8, pp. 1466- 1475 ,(1990) , 10.1200/JCO.1990.8.9.1466
B Reichman, M Markman, T Hakes, N Kemeny, D Kelsen, W Hoskins, S Rubin, J L Lewis, Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer. Journal of Clinical Oncology. ,vol. 6, pp. 158- 162 ,(1988) , 10.1200/JCO.1988.6.1.158
I. Taylor, D. Machin, M. Mullee, G. Trotter, T. Cooke, C. West, A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. British Journal of Surgery. ,vol. 72, pp. 359- 363 ,(2005) , 10.1002/BJS.1800720509
S. Bengmark, Lo. Hafström, The Natural History of Primary and Secondary Malignant Tumors of the Liver II Digestion. ,vol. 2, pp. 179- 186 ,(1969) , 10.1159/000196936
Paul H. Sugarbaker, David Chang, Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Annals of Surgical Oncology. ,vol. 6, pp. 727- 731 ,(1999) , 10.1007/S10434-999-0727-7